Cargando…

Adiponectin and the steatosis marker Chi3L1 decrease following switch to raltegravir compared to continued PI/NNRTI-based antiretroviral therapy

BACKGROUND: People with HIV are at for metabolic syndrome (MetS) and fatty liver disease, but the role of Antiretroviral therapy (ART) is poorly understood. MetS and fatty liver disease been associated with changes in adiponectin, soluble ST2 (sST2), chitinase 3-like 1 (Chi3L1), hyaluronic acid (HA)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Offor, Obiageli, Utay, Netanya, Reynoso, David, Somasunderam, Anoma, Currier, Judith, Lake, Jordan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944924/ https://www.ncbi.nlm.nih.gov/pubmed/29746485 http://dx.doi.org/10.1371/journal.pone.0196395

Ejemplares similares

Circulating LOXL2 Levels Reflect Severity of Intestinal Fibrosis and GALT CD4(+) T Lymphocyte Depletion in Treated HIV Infection
por: Seang, Sophie, et al.
Publicado: (2017)

Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
por: Stevenson, Heather L., et al.
Publicado: (2016)

376. Effect of Parasitic Infections on Gut Epithelial Barrier and Immune Activation among Foreign-Born HIV-infected Patients
por: Reimer-McAtee, Melissa, et al.
Publicado: (2019)

2517. Oral Fecal Microbiota Transplantation Increases Gut Microbiome Diversity and Alters the Microbiome Distribution in People with HIV
por: Utay, Netanya S, et al.
Publicado: (2019)

Fibrogenic Gene Expression in Hepatic Stellate Cells Induced by HCV and HIV Replication in a Three Cell Co-Culture Model System
por: Akil, Abdellah, et al.
Publicado: (2019)

Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimens
por: Manosuthi, Weerawat, et al.
Publicado: (2010)

Evaluation of Six Weekly Oral Fecal Microbiota Transplants in People with HIV
por: Utay, Netanya S., et al.
Publicado: (2020)

Raltegravir, tenofovir, and emtricitabine in an HIV-Infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver toxicity
por: Ortu, F, et al.
Publicado: (2010)

Serum Bovine Immunoglobulins Improve Inflammation and Gut Barrier Function in Persons with HIV and Enteropathy on Suppressive ART
por: Utay, Netanya S., et al.
Publicado: (2019)

1048. Weight Gain after Initiation of Anti-Retroviral Therapy in Acute HIV-1
por: Kaur, Harmanpreet, et al.
Publicado: (2020)

Switch to Raltegravir From Protease Inhibitor or Nonnucleoside Reverse-Transcriptase Inhibitor Does not Reduce Visceral Fat In Human Immunodeficiency Virus-Infected Women With Central Adiposity
por: Lake, Jordan E., et al.
Publicado: (2015)

MRSA Infections in HIV-Infected People Are Associated with Decreased MRSA-Specific Th1 Immunity
por: Utay, Netanya S., et al.
Publicado: (2016)

Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial
por: Serrano-Villar, Sergio, et al.
Publicado: (2016)

Correction: Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial
por: Serrano-Villar, Sergio, et al.
Publicado: (2016)

Correction: Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial
por: Serrano-Villar, Sergio, et al.
Publicado: (2017)

Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection
por: Chirch, Lisa M, et al.
Publicado: (2010)

Urinary Eicosanoid Metabolites in HIV-Infected Women with Central Obesity Switching to Raltegravir: An Analysis from the Women, Integrase, and Fat Accumulation Trial
por: Hulgan, Todd, et al.
Publicado: (2014)

Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens
por: Cozzi‐Lepri, A, et al.
Publicado: (2017)

Interferons and HIV Infection: The Good, the Bad, and the Ugly
por: Utay, Netanya S., et al.
Publicado: (2016)

Hepatotoxicity in patients co-infected with HIV and tuberculosis while receiving NNRTI-based antiretroviral regimen and rifampicin
por: Mankhatitham, W, et al.
Publicado: (2010)

Emergency of Primary NNRTI Resistance Mutations without Antiretroviral Selective Pressure in a HAART-Treated Child
por: Machado, Elizabeth S., et al.
Publicado: (2009)

Low-Frequency NNRTI-Resistant HIV-1 Variants and Relationship to Mutational Load in Antiretroviral-Naïve Subjects
por: Gupta, Shaili, et al.
Publicado: (2014)

Does Once-Daily Raltegravir Have Any Role in the Antiretroviral Treatment?
por: Gutierrez-Valencia, Alicia, et al.
Publicado: (2015)

Efficacy of Once Daily Darunavir/Ritonavir in PI-Naïve, NNRTI-Experienced Patients in the ODIN Trial
por: Geretti, Anna Maria, et al.
Publicado: (2015)

Acute HIV infection (AHI): Trained Service Linkage Workers and fourth-generation Assay Significantly Shorten Time to Antiretroviral Therapy Initiation.
por: Smith, Daniel, et al.
Publicado: (2017)

Immunologic and virologic failure after first-line NNRTI-based antiretroviral therapy in Thai HIV-infected children
por: Bunupuradah, Torsak, et al.
Publicado: (2011)

Transcriptional Changes in CD8(+) T Cells During Antiretroviral Therapy Intensified With Raltegravir
por: Ouyang, Zhengyu, et al.
Publicado: (2015)

Switching to a 'nuke-sparing' raltegravir/atazanavir combination: an individualised approach
por: Grant, A, et al.
Publicado: (2010)

Cost-effectiveness of 2NRTI+NNRTI versus 2NRTI+PI as the initial cART regimen
por: Aragão, F, et al.
Publicado: (2010)

Raltegravir monohydrate
por: Yamuna, Thammarse S., et al.
Publicado: (2013)

NNRTI and Liver Damage: Evidence of Their Association and the Mechanisms Involved
por: Benedicto, Ana M., et al.
Publicado: (2021)

Comparison of Illumina and 454 Deep Sequencing in Participants Failing Raltegravir-Based Antiretroviral Therapy
por: Li, Jonathan Z., et al.
Publicado: (2014)

Associations of circulating chemerin and adiponectin concentrations with hepatic steatosis
por: Levin, Lena-Maria, et al.
Publicado: (2019)

HIV resistance to raltegravir
por: Clavel, François
Publicado: (2009)

Intensification of antiretroviral treatment with raltegravir for pregnant women living with HIV at high risk of vertical transmission
por: Puthanakit, Thanyawee, et al.
Publicado: (2018)

Antiretroviral Therapy Containing Raltegravir to Prevent Mother-to-Child Transmission of HIV in Infected Pregnant Women
por: Cecchini, Diego M., et al.
Publicado: (2017)

2487. Low Rate of Virologic Failure in Antiretroviral Experienced Patients Prescribed Once Daily Raltegravir
por: Hsu, Ricky, et al.
Publicado: (2019)

Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA
por: Bianco, Claudia, et al.
Publicado: (2014)

Pre-treatment HIV-drug resistance associated with virologic outcome of first-line NNRTI-antiretroviral therapy: A cohort study in Kenya
por: Beck, Ingrid A., et al.
Publicado: (2020)

High levels of polymorphisms related to raltegravir resistance among raltegravir-naïve individuals in Brazil
por: Pena, N Mantovani, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_27ohis8ucs9bvac6qca21rus6k